SETD2 and hereditary clear cell renal cell carcinoma: Duns et al. (2010) found that the expression of SETD2 transcripts was upregulated treated with inhibitors of NMD in the renal cell carcinoma cell lines RCC-ER and RCC-AB, which harbor hemizygous mutations introducing PTCs in SETD2. This finding suggests that the degradation of the truncated SETD2 protein by the NMD is possible.